TY - JOUR
T1 - Malignancies in systemic lupus erythematosus
AU - Kale, Mruganka
AU - Ramsey-Goldman, Rosalind
AU - Gordon, Caroline
AU - Clarke, Ann E.
AU - Bernatsky, Sasha
PY - 2013/4
Y1 - 2013/4
N2 - The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.
AB - The purpose of this review is to underline important advancements in the understanding of cancer risks in systemic lupus erythematosus (SLE). In SLE, there is an increased risk of specific kinds of malignancy. For example, the risk of non-Hodgkin's lymphoma is increased several-fold in SLE versus the general population. In addition, heightened risks for lung cancer, thyroid cancer and cervical dysplasia in SLE have been found. Some have postulated that immunosuppressive drugs play a role, as well as other important mediators, such as lupus disease activity itself. One new frontier being explored is the significant finding of a decreased risk of certain nonhematologic cancers (e.g., breast, ovarian, endometrial and prostate) in SLE. The reasons for this are currently under study.
KW - cancer
KW - immunosuppressive drug
KW - malignancy
KW - risk
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=84875735802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84875735802&partnerID=8YFLogxK
U2 - 10.2217/ijr.13.11
DO - 10.2217/ijr.13.11
M3 - Review article
AN - SCOPUS:84875735802
SN - 1758-4272
VL - 8
SP - 275
EP - 280
JO - International Journal of Clinical Rheumatology
JF - International Journal of Clinical Rheumatology
IS - 2
ER -